i
Important informations
Instagram
Portail
Faire un don

Laboratoire

Le laboratoire de Michael Witcher

Research Overview
 

L’épigénétique est définie comme les facteurs moléculaires qui régulent l’activité du génome, indépendamment de la séquence de l’ADN. Ces facteurs comprennent la modification des histones, la méthylation de l’ADN et les ARN non codants. Dans notre laboratoire, nous étudions les défauts épigénétiques dans les cancers du sein et de l’ovaire. En comprenant comment ces aberrations donnent naissance au cancer, nous pouvons acquérir des connaissances essentielles qui nous permettront de développer de nouvelles approches thérapeutiques pour traiter ces maladies.

Nous utilisons des technologies classiques et de pointe pour étudier la reprogrammation épigénétique à l’échelle du génome dans le cancer et développer de nouvelles petites molécules inhibitrices ciblant les processus épigénétiques. Ces techniques comprennent la Chromatin-IP, la ChIP-seq, la RNA-seq, la micro-irradiation laser, la spectrométrie de masse, le CRISPR-Cas9 et les modèles animaux de cancer.

 
Switches


Nous pensons que les cellules cancéreuses développent un réseau de signalisation reliant le micro-environnement aux régulateurs de la chromatine, ce qui entraîne une reprogrammation épigénétique.

Notre équipe

Autexier lab members

Membres du laboratoire Witcher (de gauche à droite) : Su Jie (assistant de recherche), Dr Sofiane Berrazouane (postdoctorant), Meredyth Elisseou (étudiante diplômée), Mariam Anwar (étudiante diplômée), Eduardo Cepeda Canedo (étudiant diplômé), Emmanuel Asante (étudiant diplômé), Marios Langke (étudiant diplômé), Dr Antoine Meant (postdoctorant), Audrey Houle (étudiante diplômée), Dr Michael Witcher (chercheur principal), Dr Tiejun Zhao (assistant de recherche principal).

Recherche

Projets spécifiques dans le laboratoire
1. Comprendre les conséquences du dysfonctionnement du CTCF dans le cancer
Michael Witcher 1

 

Le CTCF est un maître régulateur multifonctionnel du génome humain. Il peut être fonctionnellement inactivé dans le cancer par plusieurs mécanismes, notamment : 1) la délétion 2) la mutation 3) la perte de la modification post-traductionnelle poly (ADP-ribosylation) 4) la mutation de ses sites de liaison à l’ADN.

 
 
 
 
 
 
 
 
 
Nous voulons explorer les conséquences épigénétiques et transcriptionnelles de ces défauts. De manière inattendue, nous avons établi un nouveau rôle pour CTCF dans la réparation des cassures double brin. Nous cherchons maintenant à savoir si cette nouvelle fonction de CTCF est perturbée dans le cancer et favorise la progression oncogénique.
 
 
 
 
Le facteur de transcription TFII-I cible le CTCF sur les gènes liés au métabolisme.
Résultats des expériences ChIP-seq.
Michael Witcher 2

Confocal

2. Le traitement de l’épigénome pour lutter contre le cancer de l’ovaire

En utilisant l’ARN-seq et la chromatine-IP, nous avons découvert des défauts épigénétiques qui nous permettent de trouver de nouvelles voies thérapeutiques pour traiter des cancers incurables.

Michael Witcher 3

Michael Witcher 4

 

 

 

 

 

 

 

 

Données RNA-seq de lignées cellulaires de cancer de l’ovaire traitées avec des médicaments ciblant l’épigénome.

 
 

 

 

 

 

 

3. Cibler la poly (ADP-ribosylation)

La poly (ADP-ribosylation) est une modification des protéines effectuée par la PARP-1. Nous avons la preuve que cette voie est anormale dans un grand nombre de cancers. En ciblant cette voie par des moyens uniques développés par notre laboratoire, nous sommes en mesure de favoriser ou de ralentir efficacement la croissance des cancers du sein primaires et métastatiques.

 
Michael Witcher 5
 
 
 
 
 
 
 
Ablation des métastases pulmonaires par la manipulation de la voie poly (ADP-ribose).
 
 
 
 
 
 
 
 
Michael Witcher 6
 
 
Cellules de cancer du sein triple négatif reprogrammées pour acquérir des caractéristiques plus physiologiques et épithéliales après modulation.

Lorem ipsum dolor sit amet consectetur adipisicing elit. Maxime mollitia, molestiae quas vel sint commodi repudiandae consequuntur voluptatum laborum numquam blanditiis harum quisquam eius sed odit fugiat iusto fuga praesentium optio, eaque rerum! Provident similique accusantium nemo autem. Veritatis obcaecati tenetur iure eius earum ut molestias architecto voluptate aliquam nihil, eveniet aliquid culpa officia aut! Impedit sit sunt quaerat, odit, tenetur error, harum nesciunt ipsum debitis quas aliquid. Reprehenderit, quia. Quo neque error repudiandae fuga? Ipsa laudantium molestias eos sapiente officiis modi at sunt excepturi expedita sint? Sed quibusdam recusandae alias error harum maxime adipisci amet laborum. Perspiciatis minima nesciunt dolorem! Officiis iure rerum voluptates a cumque velit quibusdam sed amet tempora. Sit laborum ab, eius fugit doloribus tenetur fugiat, temporibus enim commodi iusto libero magni deleniti quod quam consequuntur! 

Team

Dr. Walter Gotlieb

Walter Gotlieb, MD, PhD

Principal Investigator

After graduating with a BSc in Biology from Nebraska Wesleyan University, Koren Mann obtained a PhD in Pathology/Immunology from Boston University School of Medicine. Following that, she completed a Postdoctoral Fellowship in Oncology at McGill, where she investigated the use of arsenic as a potential chemotherapy in cancer treatment. Today, she is the Chair of the Department of Pharmacology and Therapeutics, an Associate Member of the Department of Medicine, and a Senior Investigator at the Lady Davis Institute for Medical Research.

Dr. Melica N. Brodeur

Melica Brodeur, MD, MSc

Principal Investigator

After graduating with a BSc in Biology from Nebraska Wesleyan University, Koren Mann obtained a PhD in Pathology/Immunology from Boston University School of Medicine. Following that, she completed a Postdoctoral Fellowship in Oncology at McGill, where she investigated the use of arsenic as a potential chemotherapy in cancer treatment. Today, she is the Chair of the Department of Pharmacology and Therapeutics, an Associate Member of the Department of Medicine, and a Senior Investigator at the Lady Davis Institute for Medical Research.

Michael Witcher 7

Suzie Lau, MD, MSc

Co-Investigator

After graduating with a BSc in Biology from Nebraska Wesleyan University, Koren Mann obtained a PhD in Pathology/Immunology from Boston University School of Medicine. Following that, she completed a Postdoctoral Fellowship in Oncology at McGill, where she investigated the use of arsenic as a potential chemotherapy in cancer treatment. Today, she is the Chair of the Department of Pharmacology and Therapeutics, an Associate Member of the Department of Medicine, and a Senior Investigator at the Lady Davis Institute for Medical Research.

Michael Witcher 7

Shannon Salvador, MD, MSc

Co-Investigator

After graduating with a BSc in Biology from Nebraska Wesleyan University, Koren Mann obtained a PhD in Pathology/Immunology from Boston University School of Medicine. Following that, she completed a Postdoctoral Fellowship in Oncology at McGill, where she investigated the use of arsenic as a potential chemotherapy in cancer treatment. Today, she is the Chair of the Department of Pharmacology and Therapeutics, an Associate Member of the Department of Medicine, and a Senior Investigator at the Lady Davis Institute for Medical Research.

Research Associates

Michael Witcher 7

Amber Yasmeen, PhD

Team Arsenic

Cynthia is the Mann lab manager. She offers support to the students with their projects, experiments and troubleshooting. She maintains a productive and positive lab environment. One of her projects involves the creation of arsenic 3 methyltransferase (As3MT) flox mice. These mice are an important tool in dissecting the role of tissue-specific As3MT in arsenic toxicity, as well as potentially identifying alternative As3MT functions.
Michael Witcher 7

Maroua Mbarik, PhD

Team Copper

Mitra is a research associate in the Mann Lab. After finishing her BSc in Physiology at McGill, she began her career at the Lady Davis Institute. Her project explores the role of copper, a metal commonly found in drinking water, in the progression of amyotrophic lateral sclerosis.

Clinical Research Assistant

Michael Witcher 7

Angela Tatar, MSc

Team OPE

Braeden is a PhD candidate in the Department of Pharmacology. He completed an Honours Bachelor of Science at Queen’s University with a specialization in Drug Development and Human Toxicology. His project focuses on elucidating the consequences of organophosphate esters exposure on macrophage function.

Clinical Fellows

Michael Witcher 7

Gabriel Levin, MD

Team Arsenic

Nivetha is a PhD candidate in the Department of Experimental Medicine. She completed her BSc in Biochemistry at Concordia University. Her project focuses on how a co-exposure to metals, such as arsenic and cadmium, affects the progression of atherosclerosis.

Michael Witcher 7

David Knigin, MD, PhD

Team Lymphoma

Madelyn is a PhD student in the department of Experimental Medicine. She uses mouse modelling to study Diffuse Large B Cell Lymphoma. In particular, she has found that mutations in the transcription factor STAT6 are enriched at disease relapse, and I study how this contributes to remodeling of the tumour microenvironment.

Michael Witcher 7

Rowa Bakadlag

Team Tungsten

Rowa is a PhD candidate in the department of Experimental Medicine. She completed her BSc in Microbiology and Immunology in Saudi Arabia, then completed two MScs in Genetics and Parasitology at McGill University. Her work investigates tungsten toxicity focusing on SLC2A2 as a transporter and the effects on mature B lymphocytes.

MSc Students

Michael Witcher 7

Yoav Brezinov, MD

Team Vaping

Vincenza is an MSc. Student in the Department of Pharmacology. She completed her BSc. in Pharmacology at McGill University. Her project aims to elucidate the role of e-cigarette use on the murine cardiopulmonary system. Specifically, she is focusing on metal deposition in the lungs, and the progression of atherosclerosis due to these exposures.

Michael Witcher 7

Paul-Adrien Guigue

Team Arsenic

Nazli Zengin is an MSc. student in the Department of Pharmacology. She has a background in pharmacology and environment. Her work currently focuses on elucidating how sex and diet modulate arsenic toxicity and its immunological and cardiovascular consequences.

Michael Witcher 7

Andrew Little

Team Arsenic

Andrew is an MSc. student in the Department of Pharmacology who graduated from the B.Sc. program in Biochemistry at McGill in 2021. He works on a proteomics project centred around Arsenic 3-Methyltransferase and the question about whether it serves an additional function.

Michael Witcher 7

Raymond Tu

Team Tungsten

Raymond is an MSc. Student in the Department of Pharmacology who completed his BSc. in Environmental Health Sciences from the UNC Chapel Hill as a as a Morehead-Cain Scholar. He received the McCall MacBain Scholarship in 2021. His project studies the mechanism of tungsten on mTORC1, a major regulator of cell growth and proliferation.

Michael Witcher 7

Nikola Kukolj

Team Arsenic

Nikola is an incoming MSc Student who completed his undergraduate degree in
Microbiology and Immunology at McGill University. He is currently working on an NSERC
summer project that assesses the functional characterization of macrophages exposed to arsenic using murine bone marrow-derived macrophages.

Undergraduate Students

Michael Witcher 7

Roni Juran

Team Vaping

Roni is a second-year BSc student in Chemistry at McGill. As an undergraduate student, she works on various projects across the lab, but is currently focused elucidating the correlation between nonalcoholic fatty liver disease and vaping.

Publications

  • Lebeau B, Jangal M, Zhao T, Wong CK, Wong N, Cañedo EC, Hébert S, Aguilar-Mahecha A, Chabot C, Buchanan M, Catterall R, McCaffrey L, Deblois G, Kleinman C, Park M, Basik M, Witcher M*.3D chromatin remodeling potentiates transcriptional programs driving cell invasion. Proc Natl Acad Sci. Sept 6, 2022 (IF 12.7) 
  • Lebeau B, Zhao K, Jangal M, Zhao T, Guerra M, Greenwood CMT, Witcher M*.Single base-pair resolution analysis of DNA binding motif with MoMotif reveals an oncogenic function of CTCF zinc-finger 1 mutation. Nucleic Acids Res, Aug 6, 2022 (IF 19.1) 
  • Heath J, Simo Cheyou E, Findlay S, Luo VM, Pinedo Carpio E, Lee J, Djerir B, Chen X, Morin T, Lebeau B, Karam M, Bagci H, Grapton D, Ursini-Siegel J, Côté JF, Witcher M, Richard S, Maréchal A, and Orthwein A, POGZ modulates the DNA damage response in a HP1-dependent manner.EMBO Rep., Nov 10 2021, e51041 (IF 8.8) 
  • Totten SP, Im YK, Cepeda Cañedo E, Najyb O, Nguyen A, Hébert S, Ahn R, Lewis K, Lebeau B, La Selva R, Sabourin V, Martínez C, Savage P, Kuasne H, Avizonis D, Santos Martínez N, Chabot C, Aguilar-Mahecha A, Goulet ML, Dankner M, Witcher M, Petrecca K, Basik M, Pollak M, Topisirovic I, Lin R, Siegel PM, Kleinman CL, Park M, St-Pierre J, Ursini-Siegel J. STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer.Nat Commun. 2021 Jun 3;12(1):3299. (IF 17.6) 
  • Cañedo EC, Totten S, Ahn R, Savage P, MacNeil D, Hudson J, Autexier C, Deblois G, Park M, Witcher M*, Ursini-Siegel J (Co-corresponding). p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors.JCI Insight. 2021 Feb 22;6(4):e138382 (IF 9.4) 
  • Shorstova T, Foulkes WD, Witcher M Achieving clinical success with BET inhibitors as anti-cancer agents.Br J Cancer. 2021 Mar 15. doi: 10.1038/s41416-021-01321-0 (IF 7.6) 
  • Tawil N, Bassawon R, Meehan B, Nehme A, Montermini L, Gayden T, De Jay N, Spinelli C, Chennakrishnaiah S, Choi D, Adnani L, Zeinieh M, Jabado N, Kleinman CL, Witcher M, Riazalhosseini Y, Key NS, Schiff D, Grover SP, Mackman N, Couturier CP, Petrecca K, Suvà ML, Patel A, Tirosh I, Najafabadi H, Rak J Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles.Blood Adv. 2021 Mar 23;5(6):1682-1694. (IF 7.6) 
  • Shorstova T, Su J, Zhao T, Dahabieh M, Leibovitch M, De Sa Tavares Russo M,  Avizonis A, Rajkumar S, Watson I, del Rincon SV, Miller WH JR., Foulkes WD Witcher M*. Reprogramming of nucleotide metabolism mediates synergy between epigenetic therapy and MAP Kinase inhibition. Molecular Cancer Therapeutics, 2021, Jan;20(1):64-75. (IF 6.2) 
  • Spriano F, Gaudio E, Cascione L, Tarantelli C, … Witcher M, Brown B, Wahlestedt C, Giles F, Stathis A and Bertoni Anti-tumor activity of the dual BET and CREBBP/EP300 inhibitor NEO2734. Blood Advances, 2020, Sep 8;4(17):4124-4135 (IF 7.6)  
  • Tischkowitz M, Huang S, Banerjee S, Hague J, Hendricks WPD, Huntsman DG, Lang JD, Orlando KA, Oza AM, Pautier P, Ray-Coquard I, Trent JM, Witcher M, Witkowski L, McCluggage WG, Levine DA, Foulkes WD, Weissman BE. Clin Cancer Res. 2020 Aug 1;26(15):3908-3917 (IF 13.8)
  • Roy DG, Chen J, … Witcher M, Krawczyk CM, Larochelle C, Jones RG.Methionine Metabolism Shapes T Helper Cell Responses through Regulation of Epigenetic Reprogramming. Cell Metabolism, 2020, Feb 4;31(2):250-266. (IF 27.2) 
  • Jangal M, Lebeau B, Witcher M*. Beyond EZH2: is the polycomb protein CBX2 an emerging target for anti-cancer therapy?Expert Opin Ther Targets. 2019 Jul;23(7):565-578. (IF 5.2) 
  • Shorstova T, Maud Marques M, Su J, Johnston J, Kleinman CL, Hamel N, Huang S, Alaoui-Jamali MA, Foulkes WD and Witcher M*. “Susceptibility of SMARCA4 deficient cancers to bromodomain inhibitors”. Cancer Research, 2019 May 15;79(10):2761-2774 (IF 12.7)
  • Guo Q, Li VZ, …Amant F, Witcher M, Behbod F, McCaffrey L, Alaoui-Jamali MA, Giannakopoulos NV, Brackstone M, Postovit LM, Del Rincón SV, Miller WH.MNK1/NODAL signaling promotes invasive progression of breast ductal carcinoma in situ. Cancer Research 2019, Apr 1;79(7):1646-1657 (IF 12.7)  
  • Xue Y, Meehan B, Macdonald E, Venneti S, Wang XQ, Witkowski L, Kong T, Martinez D, Morin G, Abedini A, Johnson RM, Cencic R, Chen H, Jelinic P, Papadakis A, Auguste A, de Rink I, Kerkhoven RM, Bertos N, Gotlieb WH, Clarke BA, Leary A,Witcher M, Guiot MC, Pelletier J, Dostie J, Park M, Levine DA, Judkins AR, Hass R, Rak J, Vanderhyden B, Foulkes WD and Huang S.“CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in small cell carcinoma of the ovary, hypercalcemic type”. Nature Communications, Feb 4;10(1):558. (IF 14.9) 
  • “Oncogenic activity of Poly (ADP-ribose) glycohydrolase”. Marques M, Jangal M, Wang LC, Kazanets A, da Silva SD, Zhao T, Lovato A, Yu H, Jie S, Del Rincon S, Mackey J, Damaraju S, Alaoui-Jamali M and Witcher M*. Oncogene, Mar;38(12):2177-2191. (IF 8.7)
  • Wang Z, Wang W, Cui YC, Pan Q, Zhu W, Gendron P, Guo F, Cen S, Witcher M, Liang C.“HIV-1 employs multiple mechanisms to resist Cas9/sgRNA targeting the viral primer binding site.” J Virol. 2018 Aug 1. pii: JVI.01135-18 (IF 4.5) 
  • Dahabieh MS, Di Pietro E, Jangal M, Goncalves C, Witcher M, Braverman NE, Del Rincón SV.“Peroxisomes and Cancer: The Role of a Metabolic Specialist in a Disease of Aberrant Metabolism.” BBA reviews Cancer. 2018 Jul 13. pii: S0304-419X(18)30053-2. (IF 10.6) 
  • Tang L, Morris J, Wan J, Moore C, Fujita Y, Gillaspie S, Aube E, Nanda J, Marques M, Jangal M, Anderson A, Cox C, Hiraishi H, Dong L, Saito H, Singh CR, Witcher M, Topisirovic I, Qian SB, Asano K.“Competition between translation initiation factor eIF5 and its mimic protein 5MP determines non-AUG initiation rate genome-wide.” Nucleic Acids Res. 2017 Sep 18. doi: 10.1093/nar/gkx808 (IF 16.4) 
  • Hilmi K, Jangal M, Marques M, Zhao T, Saad S, Zhang C, Luo VM, Syme A, Rejon C, Yu Z, Krum A, Fabian MR, Richard S, Alaoui-Jamali M, Orthwein A, McCaffrey L and Witcher M*. “CTCF facilitates DNA double-strand break repair by enhancing homologous recombination repair.”Science Advances (AAAS, Science). 2017 May 24;3(5):e1601898. (IF 13.1)

Collaborations

Dr. Wilson Miller, Lady Davis Institute, Montreal

Dr. Sonia del Rincon, Lady Davis Institute, Montreal

Dr. Carolyn Baglole, RI-MUHC, McGill University, Montreal

Dr. Jun Ding, RI-MUHC, McGill University, Montreal

Dr. Susan Gaskin, Department of Chemical Engineering, McGill University, Montreal

Dr. Bernard Robaire, Department of Pharmacology McGill University, Montreal

Dr. Brandon Pearson, Columbia University, New York

Dr. John Wise, University of Louisville, Kentucky

News/Milestones

Dr. Wilson Miller, Lady Davis Institute, Montreal

Dr. Sonia del Rincon, Lady Davis Institute, Montreal

Dr. Carolyn Baglole, RI-MUHC, McGill University, Montreal

Dr. Jun Ding, RI-MUHC, McGill University, Montreal

Dr. Susan Gaskin, Dep’t of Chemical Engineering, McGill University, Montreal

Dr. Bernard Robaire, Dep’t of Pharmacology McGill University, Montreal

Dr. Brandon Pearson, Columbia University, New York

Dr. John Wise, University of Louisville, Kentucky

Lorem ipsum dolor sit amet consectetur adipisicing elit. Maxime mollitia, molestiae quas vel sint commodi repudiandae consequuntur voluptatum laborum numquam blanditiis harum quisquam eius sed odit fugiat iusto fuga praesentium optio, eaque rerum! Provident similique accusantium nemo autem. Veritatis obcaecati tenetur iure eius earum ut molestias architecto voluptate aliquam nihil, eveniet aliquid culpa officia aut! Impedit sit sunt quaerat, odit, tenetur error, harum nesciunt ipsum debitis quas aliquid. Reprehenderit, quia. Quo neque error repudiandae fuga? Ipsa laudantium molestias eos sapiente officiis modi at sunt excepturi expedita sint? Sed quibusdam recusandae alias error harum maxime adipisci amet laborum. Perspiciatis minima nesciunt dolorem! Officiis iure rerum voluptates a cumque velit quibusdam sed amet tempora. Sit laborum ab, eius fugit doloribus tenetur fugiat, temporibus enim commodi iusto libero magni deleniti quod quam consequuntur! 

  1. How iMALDI can improve clinical diagnostics. Popp, R., Basik, M., Spatz, A., Batist, G., Zahedi, R.P., Borchers, C.H., 2018. Analyst Clin. Chem. 64, 1271–1272. 143, 2197–2203.
  2. Immuno-MALDI-TOF-MS in the Clinic. Zahedi, R.P., Parker, C.E., Borchers, C.H., 2018.

Awards

Walter Gotlieb:

Melica Brodeur:

Braeden Giles:

  • Centre for Research in Reproduction and Development Fellowship, 2023
  • 3 Minute Thesis – Pharmacology McGill, 2023

Andrew Little:

  • Master’s Training Scholarship – CIHR, 2022

Nikola Kukolj:

  • Undergraduate Student Research Awards – NSERC, 2023

Links

Titre

Lorem ipsum dolor sit amet consectetur adipisicing elit. Maxime mollitia, molestiae quas vel sint commodi repudiandae consequuntur voluptatum laborum numquam blanditiis harum quisquam eius sed odit fugiat iusto fuga praesentium optio, eaque rerum! Provident similique accusantium nemo autem. Veritatis obcaecati tenetur iure eius earum ut molestias architecto voluptate aliquam nihil, eveniet aliquid culpa officia aut! Impedit sit sunt quaerat, odit, tenetur error, harum nesciunt ipsum debitis quas aliquid. Reprehenderit, quia.

Titre

Events

Dr. Wilson Miller, Lady Davis Institute, Montreal

Dr. Sonia del Rincon, Lady Davis Institute, Montreal

Dr. Carolyn Baglole, RI-MUHC, McGill University, Montreal

Dr. Jun Ding, RI-MUHC, McGill University, Montreal

Dr. Susan Gaskin, Dep’t of Chemical Engineering, McGill University, Montreal

Dr. Bernard Robaire, Dep’t of Pharmacology McGill University, Montreal

Dr. Brandon Pearson, Columbia University, New York

Dr. John Wise, University of Louisville, Kentucky

Lorem ipsum dolor sit amet consectetur adipisicing elit. Maxime mollitia, molestiae quas vel sint commodi repudiandae consequuntur voluptatum laborum numquam blanditiis harum quisquam eius sed odit fugiat iusto fuga praesentium optio, eaque rerum! Provident similique accusantium nemo autem. Veritatis obcaecati tenetur iure eius earum ut molestias architecto voluptate aliquam nihil, eveniet aliquid culpa officia aut! Impedit sit sunt quaerat, odit, tenetur error, harum nesciunt ipsum debitis quas aliquid. Reprehenderit, quia. Quo neque error repudiandae fuga? Ipsa laudantium molestias eos sapiente officiis modi at sunt excepturi expedita sint? Sed quibusdam recusandae alias error harum maxime adipisci amet laborum. Perspiciatis minima nesciunt dolorem! Officiis iure rerum voluptates a cumque velit quibusdam sed amet tempora. Sit laborum ab, eius fugit doloribus tenetur fugiat, temporibus enim commodi iusto libero magni deleniti quod quam consequuntur! 

  1. How iMALDI can improve clinical diagnostics. Popp, R., Basik, M., Spatz, A., Batist, G., Zahedi, R.P., Borchers, C.H., 2018. Analyst Clin. Chem. 64, 1271–1272. 143, 2197–2203.
  2. Immuno-MALDI-TOF-MS in the Clinic. Zahedi, R.P., Parker, C.E., Borchers, C.H., 2018.

Support

To help us attain our mission to improve the lives of those affected by gynecologic cancers, we are grateful to the funding support we receive from funding agencies and private donors. With your support, we strive to make clinical meaningful discoveries in the lab to improve patient care.

Special thanks to:

Fonds de Recherche du Québec – Santé

Canadian Institutes of Health Research (CIHR)

Gloria Girls Gloria Shapiro Foundation

Canadian Foundation for Women’s Health

Francine Grzywacz Memorial Fund

Friends for Life Foundation

Garber Fund

Israel Cancer Association

Israel Cancer Research Fund

JGH Foundation

Levy Family Fund

Reseau de recherche sur le cancer

Susan and Jonathan Wener Fund

Visman Fund of Tel Aviv University

Weekend to End Women’s Cancers

Contact

Lady Davis Institute for Medical Research, Jewish General Hospital

3755 Côte Ste-Catherine Road
Montreal, Quebec H3T 1E2

Maroua Mbarik, PhD

Email:

maroua.mbarik@ladydavis.ca

Reception:

(514) 340-8260

Office:

(514) 340-8222 ext. 22760

Lab:

(514) 340-8222 ext. 24257